FY 2026 net product revenue outlook rose to $140 million-$150 million; cash and marketable securities were $201.6 million at June 30.
Autolus cited strong physician enthusiasm for AUCATZYL, targeting 65%-70% peak adult ALL margins; obe-cel trials in lupus, pediatric ALL and progressive MS remained on track.
Q2 results and margin improvement
Autolus posted Q2 net product revenue of $45.7 million, more than doubled year over year, lifted by rising demand and new centers.
Gross margin swung to 55% from 6% in Q1, reflecting lower manufacturing cost per batch and fewer inventory reserves.
Operating loss narrowed to $43.8 million; net loss improved to $39.1 million, or $(0.15) per share.
AUTL•
